Short description
Bioenvision engages in the acquisition, development and marketing of compounds and technologies primarily for the treatment of cancer.
Description
Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
New York, New York, United States, North America
Founded on
January 1, 1996
Exited on
May 29, 2007
Non-profit?
No
Acquired?
No
Employees count
1-10
Investors
Nopepepe, Cannot Access
Sign in for full access
Founders
Chris Wood